Prez-Meza, Alissen Haro-Vinueza, Cynthia Vieira, Cristina Ruiz, Diego Villavicencio, Diego Barba, Giuliana Pazmio, Karlita Hernandez, Pamela Arizo, Sebastin Chile, and Vernica Castaeda, whose dedication and expertise have been instrumental in advancing our research.Finally, we acknowledge the collaborative spirit and commitment of all those who have supported this project and helped shape its success
These are hundreds of thousands of people losing nutrients they did not know they needed to protect
Medicamentos Europa advierte que no se usen los agonistas del receptor GLP-1 para adelgazar: "tienen efectos secundarios" Los motivos son la escasez actual de estos frmacos, indicados solo para personas con diabetes tipo 2 y obesidad, y la banalizacin de su utilizacin como "dieta milagro" La Agencia Europea de Medicamentos (EMA, por sus siglas en ingls) ha dado un golpe en la mesa para tratar de poner fin a la situacin lmite que se vive en Europa con la escasez de los frmacos agonistas de los receptores de GLP-1
These medications differ in their duration of action, administration frequency, and specific formulation, yet they share a common mechanism of action
